Ultrasound Molecular Imaging With BR55, a Predictive Tool of Antiangiogenic Treatment Efficacy in a Chemo-Induced Mammary Tumor Model.
Journal
Investigative radiology
ISSN: 1536-0210
Titre abrégé: Invest Radiol
Pays: United States
ID NLM: 0045377
Informations de publication
Date de publication:
10 2020
10 2020
Historique:
pubmed:
2
4
2020
medline:
20
5
2021
entrez:
2
4
2020
Statut:
ppublish
Résumé
The aim of this study was to evaluate the added value of ultrasound molecular imaging of the vascular growth factor receptor 2 (VEGFR2) expression, using the clinical grade contrast agent BR55, for the early evaluation of antiangiogenic treatment efficacy in a chemo-induced rat mammary tumor model. In this preclinical study, chemo-induced rat mammary tumors were obtained after a single injection of N-nitroso-N-methylurea intraperitoneally in 46 prepubescent (age 38 ± 2 days) female rats. All experiments were performed under the authorization of the Direction Générale de la Santé, Geneva, Switzerland. Once tumor reached 0.8 cm in the largest cross-section, animals were enrolled in a sunitinib- or vehicle-treated group. Ultrasound molecular imaging was performed using BR55, a clinical grade targeted contrast agent against VEGFR2, before therapy and up to 72 hours. Anatomical changes of tumor over time, that is, area of the tumor largest cross-section and tumor volume, were measured in B-mode. Signal from microbubbles was detected in a nonlinear contrast mode (power modulation) using the iU22 diagnostic ultrasound system (Phillips, United States) equipped with a L12-5 linear transducer (transmit frequency 5 MHz). Peak enhancement and wash-in area under the curve were extracted from the time intensity curves generated by a dedicated quantification software for contrast ultrasound, so-called VueBox (Bracco Suisse SA, Switzerland). The signal of bound BR55 microbubbles in the tumor was quantified 10 minutes after injection. Altogether, these parameters were used to monitor tumoral response to treatment at the anatomical, functional, and molecular levels. At each time point, a cohort of tumors was harvested for the assessment of CD31 and VEGFR2 expression by immunohistochemistry staining. Under sunitinib therapy, assessment of the expression of VEGFR2 by ultrasound molecular imaging with BR55 reveals a significant difference as early as 12 hours after first dosing (-25%), whereas tumor size significant change occurs only after 24 hours. At the end of the therapeutic protocol, 72 hours after the onset of treatment, molecular changes are more marked with a 80% decrease compared with only ~40% for the anatomic parameters. Ultrasound molecular imaging observations suggesting a decrease in VEGFR2 expression in treated tumors were corroborated by semiquantitative grading of VEGFR2, showing a decrease expression over time. Functional parameters measured in the perfusion phase also show a decrease along treatment, significant for 24 hours and of 48% of peak enhancement at the end of protocol. Anatomical, functional, and molecular evaluations are feasible in a single examination using BR55 ultrasound targeted contrast agent. Ultrasound molecular imaging of VEGFR2 can depict an early response to antiangiogenic treatment in a rat mammary tumor model. This imaging modality has a potential for early assessment of each patient's response, which could be useful to take decisions on therapeutic protocol, providing as such an imaging tool for personalized medicine.
Identifiants
pubmed: 32229739
doi: 10.1097/RLI.0000000000000661
pii: 00004424-202010000-00004
doi:
Substances chimiques
Angiogenesis Inhibitors
0
Contrast Media
0
Vascular Endothelial Growth Factor Receptor-2
EC 2.7.10.1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
657-665Références
Ribatti D, Annese T, Ruggieri S, et al. Limitations of anti-angiogenic treatment of tumors. Transl Oncol. 2019;12:981–986.
Deng H, Liu W, He T, et al. Comparative efficacy, safety, and costs of sorafenib vs. sunitinib as first-line therapy for metastatic renal cell carcinoma: a systematic review and meta-analysis. Front Oncol. 2019;9:479.
Therasse P, Eisenhauer EA, Verweij J. RECIST revisited: a review of validation studies on tumour assessment. Eur J Cancer. 2006;42:1031–1039.
Choi H, Charnsangavej C, Faria SC, et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol. 2007;25:1753–1759.
Thian Y, Gutzeit A, Koh DM, et al. Revised Choi imaging criteria correlate with clinical outcomes in patients with metastatic renal cell carcinoma treated with sunitinib. Radiology. 2014;273:452–461.
Solis-Hernandez MP, Fernandez Del Valle A, Carmona-Bayonas A, et al. Evaluating radiological response in pancreatic neuroendocrine tumours treated with sunitinib: comparison of Choi versus RECIST criteria (CRIPNET_ GETNE1504 study). Br J Cancer. 2019;121:537–544.
Lassau N, Chami L, Chebil M, et al. Dynamic contrast-enhanced ultrasonography (DCE-US) and anti-angiogenic treatments. Discov Med. 2011;11:18–24.
Lavisse S, Lejeune P, Rouffiac V, et al. Early quantitative evaluation of a tumor vasculature disruptive agent AVE8062 using dynamic contrast-enhanced ultrasonography. Invest Radiol. 2008;43:100–111.
Tranquart F, Mercier L, Frinking P, et al. Perfusion quantification in contrast-enhanced ultrasound (CEUS)—ready for research projects and routine clinical use. Ultraschall Med. 2012;33(suppl 1):S31–S38.
Williams R, Hudson JM, Lloyd BA, et al. Dynamic microbubble contrast-enhanced US to measure tumor response to targeted therapy: a proposed clinical protocol with results from renal cell carcinoma patients receiving antiangiogenic therapy. Radiology. 2011;260:581–590.
Zocco MA, Garcovich M, Lupascu A, et al. Early prediction of response to sorafenib in patients with advanced hepatocellular carcinoma: the role of dynamic contrast enhanced ultrasound. J Hepatol. 2013;59:1014–1021.
Amadori M, Barone D, Scarpi E, et al. Dynamic contrast-enhanced ultrasonography (D-CEUS) for the early prediction of bevacizumab efficacy in patients with metastatic colorectal cancer. Eur Radiol. 2018;28:2969–2978.
Tranquart F, Dujardin PA, Bouche O, et al. Value of contrast-enhanced ultrasound quantification criteria for identifying patients not responding to bevacizumab-based therapy for colorectal liver metastases. Ultraschall Med. 2018;39:544–558.
Pochon S, Tardy I, Bussat P, et al. BR55: a lipopeptide-based VEGFR2-targeted ultrasound contrast agent for molecular imaging of angiogenesis. Invest Radiol. 2010;45:89–95.
Wischhusen J, Wilson KE, Delcros JG, et al. Ultrasound molecular imaging as a non-invasive companion diagnostic for netrin-1 interference therapy in breast cancer. Theranostics. 2018;8:5126–5142.
Kosareva A, Abou-Elkacem L, Chowdhury S, et al. Seeing the invisible-ultrasound molecular imaging. Ultrasound Med Biol. 2019.
Willmann JK, Bonomo L, Testa AC, et al. Ultrasound molecular imaging with BR55 in patients with breast and ovarian lesions: first-in-human results. J Clin Oncol. 2017;35:2133–2140.
Smeenge M, Tranquart F, Mannaerts CK, et al. First-in-human ultrasound molecular imaging with a VEGFR2-specific ultrasound molecular contrast agent (BR55) in prostate cancer: a safety and feasibility pilot study. Invest Radiol. 2017;52:419–427.
Bzyl J, Lederle W, Rix A, et al. Molecular and functional ultrasound imaging in differently aggressive breast cancer xenografts using two novel ultrasound contrast agents (BR55 and BR38). Eur Radiol. 2011;21:1988–1995.
Bzyl J, Palmowski M, Rix A, et al. The high angiogenic activity in very early breast cancer enables reliable imaging with VEGFR2-targeted microbubbles (BR55). Eur Radiol. 2013;23:468–475.
Grouls C, Hatting M, Rix A, et al. Liver dysplasia: US molecular imaging with targeted contrast agent enables early assessment. Radiology. 2013;267:487–495.
Hackl C, Schacherer D, Anders M, et al. Improved detection of preclinical colorectal liver metastases by high resolution ultrasound including molecular ultrasound imaging using the targeted contrast agent BR55. Ultraschall Med. 2016;37:290–296.
Sugimoto K, Moriyasu F, Negishi Y, et al. Quantification in molecular ultrasound imaging: a comparative study in mice between healthy liver and a human hepatocellular carcinoma xenograft. J Ultrasound Med. 2012;31:1909–1916.
Tardy I, Pochon S, Theraulaz M, et al. Ultrasound molecular imaging of VEGFR2 in a rat prostate tumor model using BR55. Invest Radiol. 2010;45:573–578.
Huang D, Ding Y, Li Y, et al. Sunitinib acts primarily on tumor endothelium rather than tumor cells to inhibit the growth of renal cell carcinoma. Cancer Res. 2010;70:1053–1062.
Hwang M, Hariri G, Lyshchik A, et al. Correlation of quantified contrast-enhanced sonography with in vivo tumor response. J Ultrasound Med. 2010;29:597–607.
Payen T, Dizeux A, Baldini C, et al. VEGFR2-targeted contrast-enhanced ultrasound to distinguish between two anti-angiogenic treatments. Ultrasound Med Biol. 2015;41:2202–2211.
Lang SA, Moser C, Gehmert S, et al. Contrast-enhanced ultrasound (CEUS) detects effects of vascular disrupting therapy in an experimental model of gastric cancer. Clin Hemorheol Microcirc. 2014;56:287–299.
Baron Toaldo M, Salvatore V, Marinelli S, et al. Use of VEGFR-2 targeted ultrasound contrast agent for the early evaluation of response to sorafenib in a mouse model of hepatocellular carcinoma. Mol Imaging Biol. 2015;17:29–37.
Zhou J, Wang H, Zhang H, et al. VEGFR2-targeted three-dimensional ultrasound imaging can predict responses to antiangiogenic therapy in preclinical models of colon cancer. Cancer Res. 2016;76:4081–4089.
Eschbach RS, Clevert DA, Hirner-Eppeneder H, et al. Contrast-enhanced ultrasound with VEGFR2-targeted microbubbles for monitoring regorafenib therapy effects in experimental colorectal adenocarcinomas in rats with DCE-MRI and immunohistochemical validation. PLoS One. 2017;12:e0169323.
Wang H, Lutz AM, Hristov D, et al. Intra-animal comparison between three-dimensional molecularly targeted US and three-dimensional dynamic contrast-enhanced US for early antiangiogenic treatment assessment in colon cancer. Radiology. 2017;282:443–452.
Hyvelin JM, Tardy I, Arbogast C, et al. Use of ultrasound contrast agent microbubbles in preclinical research: recommendations for small animal imaging. Invest Radiol. 2013;48:570–583.
Hudson JM, Williams R, Tremblay-Darveau C, et al. Dynamic contrast enhanced ultrasound for therapy monitoring. Eur J Radiol. 2015;84:1650–1657.
Faivre S, Ronot M, Dreyer C, et al. Imaging response in neuroendocrine tumors treated with targeted therapies: the experience of sunitinib. Target Oncol. 2012;7:127–133.
Joo I, Kim JH, Lee JM, et al. Early quantification of the therapeutic efficacy of the vascular disrupting agent, CKD-516, using dynamic contrast-enhanced ultrasonography in rabbit VX2 liver tumors. Ultrasonography. 2014;33:18–25.
Abma E, Stock E, De Spiegelaere W, et al. Power Doppler ultrasound and contrast-enhanced ultrasound demonstrate non-invasive tumour vascular response to anti-vascular therapy in canine cancer patients. Sci Rep. 2019;9:9262.
Lassau N, Lamuraglia M, Leclère J, et al. Functional and early evaluation of treatments in oncology: interest of ultrasonographic contrast agents. J Radiol. 2004;85(5 pt 2):704–712.
Mogensen MB, Hansen ML, Henriksen BM, et al. Dynamic contrast-enhanced ultrasound of colorectal liver metastases as an imaging modality for early response prediction to chemotherapy. Diagnostics (Basel). 2017;7.
Ignee A, Jedrejczyk M, Schuessler G, et al. Quantitative contrast enhanced ultrasound of the liver for time intensity curves-reliability and potential sources of errors. Eur J Radiol. 2010;73:153–158.
Lassau N, Coiffier B, Faivre L, et al. Study of Intrapatient variability and reproducibility of quantitative tumor perfusion parameters evaluated with dynamic contrast-enhanced ultrasonography. Invest Radiol. 2017;52:148–154.
Guo S, Colbert LS, Fuller M, et al. Vascular endothelial growth factor receptor-2 in breast cancer. Biochim Biophys Acta. 2010;1806:108–121.
Christensen JG. A preclinical review of sunitinib, a multitargeted receptor tyrosine kinase inhibitor with anti-angiogenic and antitumour activities. Ann Oncol. 2007;18(suppl 10):x3–x10.
Mendel DB, Laird AD, Xin X, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res. 2003;9:327–337.
Levashova Z, Backer M, Hamby CV, et al. Molecular imaging of changes in the prevalence of vascular endothelial growth factor receptor in sunitinib-treated murine mammary tumors. J Nucl Med. 2010;51:959–966.
Baetke SC, Rix A, Tranquart F, et al. VEGFR2-targeted three-dimensional ultrasound imaging can predict responses to antiangiogenic therapy in preclinical models of colon cancer. Radiology. 2016;278:430–440.
Morais C. Sunitinib resistance in renal cell carcinoma. J Kidney Cancer VHL. 2014;1:1–11.